Hikma Injectables USA Inc., Dayton, NJ

Is Hikma Injectables USA Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.

Does Hikma Injectables USA Inc. hold a New Jersey pharmacy license?

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Delaware Division of Professional Regulation also lists nonresident license AD-0010089 for Hikma Injectables USA Inc., DAYTON, NJ, status Closed, as of Nov 10, 2026.

Has Hikma Injectables USA Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Feb 10, 2023) for Hikma Injectables USA Inc. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Hikma Injectables USA Inc.
Location
Dayton, NJ
Type as FDA labels it
503B
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
0
Latest action on that page
Aug 8, 2025
FDA Data Dashboard inspections
1 inspection: 1 VAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 11 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Hikma Injectables USA Inc., a 503B facility, with 5 dated actions.

Document
Aug 8, 2025Form 483483 issued 08/08/2025fda.gov
Dec 10, 2024Regulatory meetingRegulatory Meeting Held 12/10/2024Not linked by FDA
Jun 25, 2024Form 483483 Issued 06/25/2024FDA copy (archived)
Feb 10, 2023FMD-145 letterFMD-145 Letter Issued 02/10/2023Not linked by FDA
Jun 8, 2022Form 483483 Issued 06/08/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Hikma Injectables USA Inc., Dayton, NJ (FEI number 3022897129), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 8, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30228971291171399

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 11 numbered observations in all, across 3 inspections ending Jun 8, 2022 to Aug 8, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 28, 2025 to Aug 8, 2025: 4 observations

Firm on the cover
Hikma Injectables USA Inc., 36 Stults Rd, Dayton, NJ 08810 -1540
FEI number
3022897129
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
109 Holton Street Winchester, MA 01890
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

Your firm's procedure, Standard Operating Procedure SOPDTN15125, "100% Visual Inspection of Compounded Sterile Products," Revision 3.0, effective December 30, 2024, establishes <Redacted B4> % reject rate threshold before initiating quality events for 100% visual inspection processes (Section 7.10.1 2):

1. A <Redacted B4> % rejection threshold allows nearly <Redacted B4> of manufactured units to be defective before triggering investigation. Your firm's procedures provide no rationale or scientific justification for the <Redacted B4>% reject rate threshold. The SOP fails to specify whether this threshold applies to total rejects (combination of Critical, Major, and Minor defects) or to individual defect classifications.

2. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

On 07/29/2025, black discoloration was observed on the interior HEPA bracket of the <Redacted B4> Aseptic Processing Workstation <Redacted B4> ). The <Redacted B4> was located within Room 121-B and was being utilized in the sterility testing of the following: Ketamine HCL lot# 252050004D, Diltiazem HCL lot# 251910016D and Rocuronium Bromide lot# 252050002D.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

The firm's procedure for collecting active viable air within the ISO-5 laminar airflow hood is not representative of the full duration of sterile production process. The firm will only collect <Redacted B4> of air within approximately <Redacted B4> and the <Redacted B4> production process within the laminar airflow hood lasts approximately <Redacted B4>. For example, the aseptic process for Ketamine HCL 50mg per 5mL Lot# 25150009D was initiated at <Redacted B4> on 06/10/2025. The aseptic process concluded at <Redacted B4> and the active viable air sample was only collected at 9:22am.

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

The firm' s procedure for <Redacted B4> testing (SOPDTN15300) is deficient in that <Redacted B4> can be <Redacted B4> and evaluated via <Redacted B4> test for a total of <Redacted B4> times before an investigation is conducted. For example, Event Report Form (ERF) # 2025-067 was initiated on 04/16/2025 to document <Redacted B4> testing of Rocuronium Bromide 50mg/5mL (lot# 250780001D). Per the investigation, the <Redacted B4> was <Redacted B4> with <Redacted B4> and analyzed via the <Redacted B4> test was performed. The <Redacted B4> test failed and a <Redacted B4> was conducted, and a <Redacted B4> test was performed. The <Redacted B4> test failed and conducted, and a <Redacted B4> with <Redacted B4> test was performed. The <Redacted B4> test was conducted, and a test was performed. The <Redacted B4> test failed and a <Redacted B4> was conducted, <Redacted B4> test was performed. The test failed, and an investigation was initiated. ...

Read the full 483 (PDF on fda.gov)

Inspection Jun 10, 2024 to Jun 25, 2024: 4 observations

Firm on the cover
Hikma Injectables USA Inc., 36 Stults Rd., Dayton, NJ 08810-1540
FEI number
3022897129
Establishment type on the cover
Outsourcer
FDA district office on the cover
10 Waterview Blvd. 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically:

The design and configu ra tion of <Redacted B4> syringes filling lines <Redacted B4>, and <Redacted B4> and associated enclosures do not maintain first pass HEPA-filtered laminar flow air over all critical areas to include open syringes and tamper evident syringe caps handled within the ISO 5 classified filling enclosures.

1. The following video recordings of airflow visualization studies conducted in each of the <Redacted B4> syringe filling line <Redacted B4>, and <Redacted B4> demonstrate objectionable airflow patterns including turbulence and upward circulating air adjacent to and above open syringes and tamper evident syringe caps in the ISO 5 classified loading zone. This airflow condition was accepted and approved by your firm management without corrective actions:

<R edacted B4> syringe fi lling line <Redacted B4 > Video s ide ntified as: <Redacted B4> Loading <Redacted B4> Room <Redacted B4> <Redacted B4> Loading <Redacted B4> Room <Redacted B4>.

<Redacted B4> syringe filling line<Redacted B4>. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically:

1. You do not perform active air sampling for airborne viable monitoring in the ISO 5 classified syringe filling and capping zone of your <Redacted B4> syringe filling lines <Redacted B4>, and <Redacted B4> during syringe filling operations for drug products including Phenylephrine HCL 1 mg per 10 ml (100 mcg/ml) in 0.9% Sodium Chloride Injection, Lot# <Redacted B4> Compounders reach with their gloved hands and gowned arms into the ISO 5 filling/capping zone within the filling lines enclosures to make drug product flow path aseptic connections and to perform filling operations interventions such as removing a cap stuck in the capping fixture.

filling/capping zone within the filling lines enclosures to make diug product flow path aseptic connections and to perfo1m filling operations inte1ventions such as removing a cap stuck in the capping fixture.

2. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Samples taken of drug products for determination of conformance to written specifications are not representative.

Specifically:

You do not ensure that compounded finished drug product samples for quality control testing and disposition of the lot are representative of each sub-assembly when a sub-assembly batch process is followed in compounding and filling operations. Your procedure, SOPDTN15106, Finished product sampling procedure, specifies that "Sampling should be done from the <Redacted B4> of the lot (if applicable) to retrieve a composite sample." For example:

1. Phenylephrine HCL 1 mg per 10 ml (100 mcg/ml) in 0.9% Sodium Chloride Injection Lot# <Redacted B4> was compounded as <Redacted B4> and filled into syringe primary packaging on <Redacted B4> syringe filling line <Redacted B4>. According to the master batch record, quality control sample collection for microbiology consisted to <Redacted B4> samples for sterility testing and <Redacted B4> samples for endotoxin testin ; quality control sample collection for chemistiy testing consisted of <Redacted B4> samples for ID/Potency, <Redacted B4> for Appearance, pH, and <Redacted B4> samples for Sub-Visible Particles. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically:

You do not fully follow your written procedure SOPDTNl 5087, Growth Promotion Test, to confnm the ability of a new batch of media to support growth of a predetermined selection of representative microorganisms to include environmental isolates. Performance of growth media including those used for drug product sterility testing, environmental monitoring, and aseptic process simulation is not demonstrated through use of select "<Redacted B4>" in growth promotion testing in accordance with your procedure SOPDTN15087, Growth Promotion Test.

Inspection May 23, 2022 to Jun 8, 2022: 3 observations

Firm on the cover
Hikma Injectables USA Inc, 36 Stults Rd, Dayton, NJ 08810-1540
FEI number
3022897129
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically:

I. a.

On 05/24/2022 during the aseptic filling of Ketamine HCL 50 mg per ml Injection, NDC <Redacted B4>, Lot No: <Redacted B4> in cleanroom 142-6 within ISO 5 <Redacted B4> Laminar Flow Hood: <Redacted B4>, we observed that airborne particulate monitoring was performed <Redacted B4> for approximately <Redacted B4> during the operation. You do not provide scientific justification for the frequency and duration of airborne particulate monitoring performed during aseptic operations in the critical zone of the ISO 5 <Redacted B4> Laminar Flow Hood. Your airborne particulate monitoring program for aseptic operations is not designed and conducted to provide meaningful data to support the quality of your drug products intended to be sterile. You do not monitor airborne particulates to ISO 5 air classifications throughout aseptic operations and the orientation of the particle counter <Redacted B4> is not directed into the flow of air during monitoring. For example:

b. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically:

You have not evaluated the airflow pattern in all your ISO 5 <Redacted B4> Laminar Flow Hoods under <Redacted B4> conditions stimulating <Redacted B4> aseptic operation performed in each hood during sterile-to-sterile compounding and aseptic filling of your drug products intended to be sterile. Inspectional evaluation of your ISO 5 area airflow pattern studies; Document No: <Redacted B4> Risk Assessment Regarding the Equivalency of the LFH through the process of <Redacted B4> smoke studies, Approved Date: 05/26/2022; and List of Commercial Batches Compounded related with hood smoke studies in <Redacted B4> revealed that <Redacted B4> products/lots were roduced during the period 02/22/2022 to the present through ase tic operations performed in ISO 5 <Redacted B4> Laminar Flow Hoods for which there was no direct <Redacted B4> airflow pattern evaluation. ...

Read the full 483 (PDF on fda.gov)

Observation 3

An adequate number of batches of each drug product are not tested to determine an appropriate expiration date. Specifically,

Your drug product stability program for commercial drug products labeled with a <Redacted B4> does not include data from direct testing of those products produced in your facility. To -ate you ave not placed any drng products/lots produced in your facility on a stability testing program . Your stability program and current <Redacted B4> for all drug products is based on data derived from testing of stability products/lots produced for this purpose in other facilities.

2. Your drug product stability program for commercial drug products labeled with a <Redacted B4> does not include testing of container closure integrity at or beyond the labeled <Redacted B4>. For example: your Report# <Redacted B4> Compounding Development and Stability Report for 50mg/ml Fentanyl Citrate Injection (PF) for the Dayton Outsourcing Facility does not include container closure integrity testing results for a timepoint at or beyond the labeled <Redacted B4>.

State board of pharmacy records

State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0010089Outsourcing Facility-DistributorHikma Injectables USA Inc.DAYTON, NJClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.